Company profile
Pfizer, Inc.
Pipeline10 assets
- BerobenatidePF-06954522 / GLP-1/GIP / Small Molecule / Internal MedicineChronic Weight ManagementPhase 2bOngoingGlobal
- elranatamabPF-06863135 / ELREXFIO / BCMA x CD3 / Bispecific Antibody / OncologyDouble-class Exposed Relapsed / Refractory Multiple MyelomaPhase 3OngoingGlobal
- ritlecitinibPF-06651600 / LITFULO / JAK3/TEC / Small Molecule / Inflammation and ImmunologyVitiligoPhase 3OngoingGlobalModerate Alopecia AreataPhase 3OngoingGlobal
- marstacimabPF-06741086 / HYMPAVZI / TFPI / Monoclonal Antibody / Rare DiseaseHemophilia A/B with InhibitorsRegistrationOngoingGlobal
- MevrometostatPF-06821497 / EZH2 / Small Molecule / Oncology1-2L Metastatic Castration-resistant Prostate Cancer Post-abirateronePhase 3OngoingGlobal
- Sigvotatug vedotinPF-08046047 / Integrin beta-6 / Antibody-Drug Conjugate (ADC) / OncologyNon-Small Cell Lung Cancer (NSCLC)Phase 3OngoingGlobal
- VepdegestrantARV-471 / Estrogen Receptor (ER) / PROTAC Protein Degrader / OncologyER+/HER2- Metastatic Breast CancerPhase 3OngoingGlobal
- PCV25PF-07872412 / Pneumococcus / Vaccine / VaccinesPneumococcal InfectionPhase 3OngoingGlobal
- enfortumab vedotinPADCEV / Nectin-4 / Antibody-Drug Conjugate (ADC) / OncologyMuscle-invasive Bladder Cancer (Bladder Sparing)Phase 3OngoingGlobal
- Lyme Disease Vaccine CandidatePF-07307405 / Borrelia burgdorferi OspA / Vaccine / VaccinesLyme Disease InfectionPhase 3OngoingGlobal